The Argus Report
ZURICH (Reuters) - Lonza aims to speed completion of two commercial production lines for Moderna Inc’s trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful, the Swiss drugmaker’s chairman said on Tuesday. FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its…
Read More »Exclusive: Lonza sets new goal to make Moderna COVID-19 vaccine ingredients
